Home › Islet Cell Adenoma › Michigan
Islet Cell Adenoma clinical trials in Michigan
3 studies for Islet Cell Adenoma are looking for participants at sites in Michigan.
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Henry Ford Cancer- Detroit, Detroit
- The Cancer and Hematology Centers, Grand Rapids
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06943755Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- University of Michigan ( Site 0126), Ann Arbor
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 25, 2026 · NCT04924075Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
- University of Michigan Comprehensive Cancer Center, Ann Arbor
- University of Michigan - Brighton Center for Specialty Care, Brighton
- Henry Ford Cancer Institute-Downriver, Brownstown
- and 8 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT05040360From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.